As we further develop our global footprint, the Daiichi Sankyo Group is committed to improve access of our medicines to patients, by implementing pricing strategies which include value based pricing and equitable pricing both at inter- and intra - country level, always taking account of variances in healthcare systems, a national income level, and other environments which influence access to healthcare. We also strive to provide timely and appropriate support to patients who need our medicines and face difficulties to obtain access due to coverage limitation.